Research ArticleInfectious Disease

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

See allHide authors and affiliations

Science Translational Medicine  16 Mar 2016:
Vol. 8, Issue 330, pp. 330ra36
DOI: 10.1126/scitranslmed.aaf1517

Dengue model rises to the challenge

Human efficacy testing remains a major hurdle in bringing new vaccine candidates to the clinic. In the absence of accepted correlates of protection, rounds of safety trials must be performed before efficacy can be tested in a large population in an endemic area. Kirkpatrick et al. have developed a controlled dengue human challenge model to assess the protective efficacy of the most clinically advanced dengue vaccine candidate. They found that TV003, a live attenuated dengue vaccine that induces antibodies to all four dengue virus serotypes, protected against infection of an attenuated virus in 21 recipients when compared with 20 nonvaccinated controls. This model may serve as an early check for dengue vaccine candidates, limiting the risk of conducting large unsuccessful trials.

View Full Text

Stay Connected to
   Science Translational Medicine